Over the last few decades, the fragment-based drug design (FBDD) process has matured into a popular and effective approach to designing novel binders . Indeed during the 2015 to 2019 period, over 131 successful fragment-to-lead campaigns were published . With an intuitive structure-based approach, and ability to more easily sample a large chemical space, FBDD has become a strong contender to more traditional high-throughput screening methods.